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S U M M A R Y
Objective: African potato (Hypoxis obtusa) is commonly used in Sub-Saharan Africa as a complementary
herbal remedy for HIV-infected patients. It is unknown whether or not co-administration of African
potato alters the pharmacokinetics of protease inhibitor antiretrovirals. The objective of this study was
to investigate the impact of the African potato on the steady-state pharmacokinetics of ritonavir-boosted
lopinavir (LPV/r).
Methods: Sixteen adult volunteers were administered LPV/r 400/100 mg twice a day for 14 days,
followed by concomitant administration with African potato given once daily for 7 days. Lopinavir
plasma exposure as estimated by the area under the concentration–time curve over the 12-h dosing
interval (AUC0–12h, AUCt) was determined on day 14 and again on day 21. Lopinavir in plasma was
analyzed using a validated liquid chromatography with tandem mass spectrometry (LC-MS/MS) method.
Steady-state AUCt and the maximum concentration following dose administration (Cmax) were
determined using non-compartmental methods using WinNonlin Professional version 5.2.1. Statistical
analyses were performed using Stata version 12.1.
Results: Co-administration of African potato was not associated with any change in lopinavir AUCt, Cmax,
or Ctrough.
Conclusions: African potato when taken concomitantly with LPV/r is well-tolerated and not associated
with clinically signiﬁcant changes in lopinavir pharmacokinetics.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
The concomitant use of complementary and alternative
medicines in both developing and developed nations is common-
place. More than 30% of HIV-infected patients in Uganda use
complementary medicines concomitantly with antiretroviral
medicines.1,2 More than 70% of patients with HIV infection in
South Africa3 and US African- Americans use these medicines
together.4 Similarly, the use of herbal medicines in Zimbabwe is
estimated to be over 68% in HIV patients.5,6 This widespread use of
herbal medicines in combination with conventional treatments for
HIV may result in unanticipated herb–antiretroviral interactions.* Corresponding author. Tel.: +1 415 476 8010; fax: +1 415 476 6632.
E-mail address: guglielmoj@pharmacy.ucsf.edu (B.J. Guglielmo).
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http://dx.doi.org/10.1016/j.ijid.2013.02.017Lopinavir/ritonavir (LPV/r) is a potent HIV protease inhibitor
combination used with other anti-HIV medicines for the
treatment of HIV infection.7–9 Lopinavir (LPV), metabolized
primarily by hepatic and gastrointestinal cytochrome p450 3A
(CYP3A), is pharmacokinetically ‘boosted’ by ritonavir (RTV)
through inhibition of CYP3A.7,10,11 Since LPV and RTV are both
substrates for and inhibitors of CYP3A4, caution is warranted in
the case of co-administration of LPV/r with medicinal products
that are CYP3A4 substrates and/or may alter CYP3A4 activity. St
John’s wort (Hypericum perforatum), a known potent inducer of
CYP3A4, increases clearance of indinavir, another protease
inhibitor that is a substrate of CYP3A4.12 Consequently, St John’s
wort is contraindicated while taking LPV/r due to the risk of
decreased plasma concentrations and the potential for decreased
efﬁcacy.7
The genus Hypoxis, which is also commonly known as African
potato, is a genus of plants belonging to the Hypoxidaceae family.ses. Published by Elsevier Ltd. All rights reserved.
Figure 1. Schematic of the dosing regimen and pharmacokinetic sample collection.
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hydrolyzed to its aglycone form, rooperol, which is a bioactive
dicatechol agent shown to have anti-cancer,13 antibacterial, and
anti-inﬂammatory properties in vitro.14 In Sub-Saharan Africa,
Hypoxis is widely distributed, with over 40 species, including
Hypoxis obtusa and Hypoxis hemerocallidea. Hypoxis hemerocallidea
is a popular species in South Africa for its use in African traditional
remedies and is commonly used for its immune-boosting
properties in HIV patients, despite the lack of scientiﬁc evidence
of clinical efﬁcacy.15 Hypoxis obtusa is found in Zimbabwe,
Mozambique, and Kenya.16
In vitro studies with human liver microsomes indicate that
extracts of Hypoxis obtusa and Hypoxis hemerocallidea have a
signiﬁcant inhibitory effect on CYP3A4, the primary isozyme
responsible for the metabolism of LPV/r.17,18 Multi-drug therapy
has been found to be more effective for HIV/AIDS therapy, and less
likely to be associated with the development of resistance. It is
important to know whether or not the Hypoxis obtusa causes a
reduction in exposure that might result in reduced efﬁcacy. Also,
an increase in exposure could be associated with an increased
lipid/diabetes risk. While in vitro data suggest a signiﬁcant
interaction between Hypoxis and LPV/r, the impact of co-
administration of Hypoxis obtusa and LPV/r has not been evaluated
in vivo. The objective of this study was to investigate the in vivo
effects of Hypoxis obtusa on the clinical pharmacokinetics (PK) of
LPV/r.
2. Methods
2.1. Study population
Healthy HIV-seronegative adult volunteers between the
ages of 18 and 60 years, weighing at least 50 kg, and within
20% of their ideal body weight, were eligible for enrollment.
Female subjects were required to have a negative pregnancy
test at screening, to practice adequate birth control, and to be
non-lactating at the time of enrollment. Subjects were
required to abstain from consuming grapefruit and the use of
alcohol and tobacco for at least 48 h before entry and
throughout the study period until the last blood samples had
been obtained.
Participants with a recent history of illicit drug use or alcohol
use, who were using over-the-counter or prescribed medicines
known to inhibit/induce CYP450 isozymes or that are substrates
of CYP3A4, CYP2D6, CYP2C8 enzymes including oral contra-
ceptives, those with evidence of an acute illness, family history
of congenital prolongation of the QTc interval or with any
conditions known to prolong the QTc interval, such as cardiac
arrhythmias, bradycardia or severe heart disease, and those with
a history of hypokalemia, hypomagnesemia, or hypercholester-
emia were excluded from participating in this study. Subjects
were restricted from taking any medications other than the
study medications without the prior approval of the study
physicians.
2.2. Study setting and ethical conduct of the study
All subjects were admitted to the University of California San
Francisco (UCSF) Clinical Research Center at San Francisco
General Hospital on the evening of study days 13 and 20. The
study was reviewed and approved by the UCSF Committee on
Human Research before initiation of study activities. The study
was conducted in accordance with the protocol, pertinent
requirements of the Committee on Human Research ethics
guidelines, and the Declaration of Helsinki. Informed consentwas obtained from the volunteers before performing any study-
related activities.
2.3. Study design and treatment
This study was an open-label two-period ﬁxed sequence
cross-over PK drug interaction study to investigate the effect of
African potato on the steady-state PK of LPV/r (Figure 1). Each
subject received LPV/r alone for 14 days, followed by LPV/r plus
African potato until day 21. LPV/r was administered at the
recommended daily dose of 400 mg/100 mg twice daily. The
recommended dosing of African potato is 15 mg/kg/daily of
hypoxoside; four capsules of African potato (containing 320 mg
hypoxoside) as a single dose once a day in the morning were
administered to each subject for 7 days. Subjects were required
to fast at least 10 h before until 4 h post administration of the
study medicines on days 14 and 21, respectively. The dosing
on these study days was observed by Clinical Research Center
staff following the overnight fast. Self-reporting and a pill count
took place to ensure that participants adhered to the study
protocol.
2.4. Pharmacokinetic sampling and drug concentration assays
Subjects were conﬁned to the San Francisco General Hospital
Clinical Research Center from at least 10 h before to 12 h following
administration of the study dose on days 14 and 21. A total of nine
blood samples (5 ml each) were collected pre-dose (within 1 h
before dosing) and at 1, 2, 4, 6, 8, and 12 h post-dose for each study
period. A physical examination and vital examination was done
during screening, at the time of admission to and discharge from
the Clinical Research Center, and at the time of the post-study
follow-up visit.
LPV/r (Kaletra; manufactured by Abbott Laboratories, USA) and
the African potato (manufactured by Herbal Solutions, Harare,
Zimbabwe) were used in the study. The liquid chromatography
with tandem mass spectrometry (LC-MS/MS) system consisted of
twin PE 200 micro LC pumps, a PE 200 autosampler (Perkin-Elmer,
Norwalk, CT, USA), and the API 2000 triple quadrupole mass
spectrometer (AB Sciex, Concord, Ontario, Canada). Chro-
matographic separation was achieved on a Zorbax C8 column
(50  2.1 mm, 5 mm; Agilent Technologies Inc., Santa Clara, CA,
USA). All chemicals were of HPLC grade.
Samples for PK analysis were analyzed within the Drug
Research Unit of the Department of Clinical Pharmacy. Plasma
samples were stored at 70 8C until analysis. Lopinavir was
quantitated using a validated liquid chromatography tandem mass
spectrometry method (LC tandem MS). Brieﬂy, 50 ml of plasma
sample was mixed with 150 ml ammonium formate (10 mM, pH
4.0) and 50 ml internal standard (methyl indinavir) (0.8 mg/ml),
and then 400 ml acetonitrile was added and vortex-mixed for 15 s.
After centrifugation at 20 000 g for 10 min, the sample was
transferred to an autosampler vial. The injection volume was 10 ml.
Electron spray ionization in positive mode (ESI+) was used for ion
Figure 2. Mean steady-state plasma lopinavir concentration–time proﬁles with and
without African potato (n = 16): *, LPV in 400/100 mg LPV/r doses twice daily
(n = 16); &, LPV in 400/100 mg LPV/r doses twice daily plus African potato four
capsules once daily (n = 16).
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chosen for quantiﬁcation. The precursor-product ion pairs for
quantiﬁcation were m/z 630!429 for LPV and m/z 629!421 for
the internal standard. Samples from treatments A and B for each
subject were analyzed in a single run. The linearity range of
0.050 mg/ml to 8.0 mg/ml for LPV was used to quantify concentra-
tion in subject plasma samples. The calibration curves consisted of
eight non-zero calibrators for LPV.
2.5. Efﬁcacy and safety measurements
Safety was evaluated by monitoring adverse events, vital signs,
and laboratory results during the study period and through self-
reporting by subjects. Clinical laboratory tests monitored during
the study included the complete blood count (CBC) with
differential, liver function tests (LFTs), and lipid proﬁle. These
tests were conducted before enrollment (during screening), on
days 14, 18, and 21, and at 2 weeks, on completing the study
(follow-up visit).
2.6. Pharmacokinetic analysis
The following LPV PK parameters were determined on day 14
after LPV/r alone and day 21 after LPV/r plus African potato: area
under the concentration–time curve over the 12-h dosing interval
(AUC0–12h, AUCt), maximum concentration following dose admin-
istration (Cmax), concentration at the end of the dosing interval
(Ctrough), time to maximum concentration following dose admin-
istration (Tmax), and apparent clearance (CLF). The primary PK
parameters AUC0–12 h (AUCt) and Cmax, and the secondary PK
parameters Ctrough, Tmax, half-life (T1/2), and (elimination rate
constant Kel), were derived from plasma concentrations of LPV for
each individual by non-compartmental methods using WinNonlin
Professional version 5.2.1 (Pharsight Corp., USA). The maximum
concentration following dose administration and Tmax were taken
directly from the plasma concentration–time proﬁles of individual
subjects. The AUCt in ng*h/ml was calculated by linear trapezoidal
rule from the measured data points from time of administration
until 12 h post-dose. The Kel was calculated as the negative slope of
the log-linear terminal portion of the plasma concentration versus
time curve using linear regression with 1/x2 weighting. A
minimum of three concentrations were considered. The T1/2 was
estimated from the elimination rate constant using T1/2 = 0.693/
Kel.
2.7. Statistical analysis
Statistical analyses were performed using Stata version 12.1
(StataCorp, TX, USA). Based on the intra-subject coefﬁcient of
variation of 15% for PK parameters for LPV,19 a 5% consumer riskTable 1
Summary of steady-state plasma LPV pharmacokinetic parameters following repeated 
Arithmetic mean (SD) Geometri
LPV/r LPV/r plus AP LPV/r 
AUCt (mg*h/ml) 94.40 (25.11) 93.18 (26.76) 90.78 
Cmax (mg/ml) 10.06 (1.99) 10.18 (2.25) 9.86 
Ctrough (mg/ml) 4.85 (2.18) 4.90 (2.61) 4.13 
Tmax (h)
a 4 (1, 8) 4 (1, 10) - 
CLF (l/h) 4.61 (1.56) 4.64 (1.32) - 
AUCt, area under the concentration–time curve within a dosing interval; Cmax, maximum
end of the dosing interval; 90% CI, 90% conﬁdence interval of the geometric mean ratio; CL
100 mg (alone) twice daily for 14 days; LPV/r plus African potato, lopinavir/ritonavir 400/
point estimate of the ratio of geometric means of LPV/r plus African potato and LPV/r;
a Median (minimum, maximum).with 80% power, and assuming no difference between treatments,
16 subjects were necessary to demonstrate equivalence within the
conventional acceptance range of 0.80–1.25 applied for bioequiv-
alence studies.20
Arithmetic means and standard deviations were calculated on
the individual concentrations. Ratios of the means were calculated
using the geometric mean (GM) of log-transformed Cmax, Ctrough,
and AUCt. Ratios of means are expressed as a percentage of the GM
of the LPV/r alone. The test of bioequivalence between LPV/r alone
and in combination with African potato was assessed using the 90%
conﬁdence interval for the GM ratios for the PK parameters. To
conclude a lack of interaction/effect, the 90% conﬁdence intervals
within 80–125% for the AUCt and Cmax was used.
20 The Wilcoxon
signed-ranks test was used to test for statistical signiﬁcance in the
median Tmax. Descriptive statistics were used to evaluate adverse
events (AEs) occurring during the study.
3. Results
3.1. Demographics and baseline characteristics
Sixteen subjects (12 males, four females) were enrolled and
completed the study. The median (range) age of subjects was 28
years (19–53 years). The median (range) weight was 78.4 kg (53.3–
96.0 kg) and body mass index was 25.2 kg/m2 (19.0–31.9 kg/m2).
Four subjects whose weight was outside the inclusion criterion of
20% of ideal body weight were enrolled in the study. This protocoldose administration (n = 16)
c means PE 90% CI CV (%)
LPV/r plus AP
89.66 98.77 91.81–106.25 15.10
9.95 100.90 94.48–107.76 16.78
4.38 105.98 86.81–129.38 48.00
- - - -
- - - -
 concentration following dose administration; Ctrough, plasma concentration at the
F, apparent clearance; CV (%), coefﬁcient of variation; LPV/r, lopinavir/ritonavir 400/
100 mg twice daily plus African potato (four capsules) once daily for 7 days; PE is the
 SD, standard deviation from the mean; Tmax, time to reach Cmax.
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since each subject acted as their own control. All 16 subjects who
completed the study were included in the PK and statistical analysis.
3.2. Effect of African potato on LPV steady-state pharmacokinetics
Steady-state plasma concentration–time proﬁles of LPV with
and without African potato were similar (Figure 2). Relative to
repeated administration of LPV/r alone, the steady-state PK
parameters Cmax and AUCt of LPV remained unchanged following
concomitant administration of multiple-dose African potato
(Table 1). The corresponding 90% conﬁdence intervals were within
the 80–125% limit, indicating a lack of clinically signiﬁcant
interaction. There was no statistically signiﬁcant difference
(p = 0.5488) in Tmax between the two treatments based on the
Wilcoxon signed-ranks test. The data on Ctrough were inconclusive
(Table 1) since the upper conﬁdence limit was marginally outside
the acceptance limit and the conﬁdence interval included point
estimate = 100.
3.3. Safety and tolerability
The study medications were generally well tolerated through-
out the study. There were no serious adverse events observed in
the study. As expected, there were a few cases of mild diarrhea and
headache on LPV/r initiation. These were considered mild and
resolved after a few days on the LPV/r medication. Total cholesterol
and triglycerides were elevated but within limits during LPV/r
treatment, except in one subject with grade 1 elevation (<400 mg/
dl) in triglyceride concentrations. There were no clinically
signiﬁcant changes in vital signs or laboratory results in both
treatments during the study.
4. Discussion
To our knowledge, our study is the ﬁrst in vivo trial to evaluate
the impact of co-administration of any African herbal remedy and
antiretroviral protease inhibitors. We speciﬁcally elected to study
the African potato due to its documented wide usage in Sub-Saharan
Africa. LPV/r was the selected antiretroviral due to its primary role in
the treatment of HIV, as well as its known risk for multiple drug
interactions. Our study demonstrated that the African potato had no
signiﬁcant effect on the steady-state pharmacokinetics of LPV
boosted with RTV. While previous in vitro studies have noted a
signiﬁcant Hypoxis effect on CYP3A4,17,18 this interaction was not
observed in vivo. Our conﬁrmation of a lack of clinically signiﬁcant
interaction is consistent with that observed with the co-adminis-
tration of Hypoxis hemerocallidea and efavirenz.21 Of note, while
AUCt and Cmax were highly consistent among subjects, LPV trough
concentrations were found to be highly variable. The reasons for this
ﬁnding are unknown.
Hypoxoside is rapidly converted to its aglycone, rooperol, in the
gastrointestinal tract by beta-glucosidase enzymes.22Consequently,
it is possible that the plasma concentrations of hypoxoside achieved
in plasma following oral administration were low compared to the
concentrations used in previous in vitro experiments.
Ritonavir, a potent inhibitor of CYP3A4 is included in the LPV
formulation to boost the plasma levels of LPV.10,11 Consequently, it
is conceivable that the lack of effect with African potato on LPV
pharmacokinetics may have been confounded by the presence of
RTV. However, considering that the standard of care is RTV-
boosting of LPV or other protease inhibitors, results suggest a lack
of clinically important pharmacokinetic drug interactions with
African potato and RTV-boosted protease inhibitor regimens.
In conclusion, the concomitant administration of usual doses of
African potato with RTV-boosted LPV is not associated withclinically signiﬁcant pharmacokinetic changes in LPV/r. We
conclude that African potato can be safely administered concomi-
tantly with LPV/r.
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